Peptides vs. Steroids: A Powerlifter's Guide to Anabolic Potency

Peptides Aren't Steroids

A common question on lifting forums is which peptide comes closest to an anabolic steroid like trenbolone. The short answer is none of them.

Thinking of peptides as a 1-to-1 replacement for anabolic-androgenic steroids (AAS) is the fastest way to get disappointed. AAS work primarily by directly binding to the androgen receptor, which raises muscle protein synthesis in muscle and many other tissues. In a 1996 trial in 43 healthy men, 600 mg of testosterone enanthate a week for 10 weeks, combined with weight training, added about 6.1 kg of fat-free mass and raised bench-press strength by about 22 kg. No peptide has a human trial showing anything close.

Peptides are a different class of tool entirely. Most of the ones discussed here are signaling molecules that work upstream, not synthetic hormones. They might ask the pituitary to release more growth hormone (GH), or mimic a fraction of IGF-1's effects in a specific tissue. That upstream position limits how large their effect can be, and it's one reason human data on muscle outcomes are so thin.

Tier 1: The IGF-1 Axis - The Closest You'll Get to Direct Anabolism

If you're looking for the most directly anabolic effect from a peptide, the conversation usually starts with IGF-1 variants. Insulin-like growth factor 1 is the primary mediator of growth hormone's anabolic effects: when GH reaches the liver and other tissues, IGF-1 is what comes out. Using a variant skips that step. The catch is that none of the modified variants sold to lifters has been tested for muscle growth in humans or approved for any use, and WADA's 2026 Prohibited List bans IGF-1 and its analogues at all times (S2.3).

The Main Players

• IGF-1 LR3: This is the long-acting version. The "LR3" modification makes it bind poorly to the IGF-binding proteins that normally hold IGF-1 in the blood. Vendor guides often say this extends its half-life from minutes to 20-30 hours, but no human pharmacokinetic study exists. The rat data point the other way: in a 1999 wound-chamber study, LR3 cleared faster than native IGF-1 (half-life about 563 vs. 872 minutes). Users credit it with both hypertrophy (making existing muscle cells bigger) and hyperplasia (creating new muscle cells), but as of October 2026 no human study has measured either; the evidence is preliminary.
• IGF-1 DES: This is the short-acting variant, des(1-3)IGF-1. Forum guides often describe it as about ten times more potent than standard IGF-1, with a half-life of 20-30 minutes; we found no human measurement of either. In a 1997 study in pigs and marmoset monkeys, it was the most potent IGF-1 variant tested, at about 2-3 times IGF-1 for lowering blood sugar. Users describe it almost exclusively for site-specific use: a small dose (commonly 20-50 mcg) injected into the muscle belly right after training that muscle. No study has tested this protocol.
• MGF (Mechano Growth Factor): The name comes from a splice variant of the IGF-1 gene that muscle switches on after mechanical stress (i.e., lifting weights). In lab and animal studies, the rise in this variant tracks activation of satellite cells, the dormant stem cells muscle uses to repair damage and build new fibers. A 2010 review in Endocrinology adds a caveat: the synthetic MGF peptide corresponds to the tail end of that splice variant, but no matching natural peptide has been isolated from cells or tissue. We found no human trial.

These still aren't "legal steroids." They lack the androgenic component: they don't act on the androgen receptor, which drives much of the strength and recovery effect of AAS. They also carry a significant and immediate risk: hypoglycemia. In the 1997 pig and monkey study, IGF-1 variants that bind poorly to binding proteins, including LR3 and DES, kept blood sugar suppressed far longer than native IGF-1 (about 4-8 times the total drop over four hours). Users report shakiness, sweating and tunnel vision, and many eat carbohydrates within about 30 minutes of injecting to prevent it. That's community practice, not a tested protocol.

Tier 2: GH Secretagogues - Building the Foundation

This is the most common form of performance-focused peptide use. Growth hormone secretagogues don't provide GH themselves; they signal your own pituitary gland to produce and release more of it. Supporters call this safer than injecting exogenous HGH, since the body's feedback loops stay in place, but no trial has compared the two. Most interest centers on combining two different classes of secretagogues.

• GHRH (Growth Hormone Releasing Hormone) analogues: These peptides (like Mod GRF 1-29 or CJC-1295 no DAC) bind to the GHRH receptor. They tell the pituitary how much GH to produce in its next pulse.
• GHRP (Growth Hormone Releasing Peptide) analogues: These peptides (like Ipamorelin or GHRP-2) bind to a different receptor, the GHS-R, which is also the receptor for ghrelin. They tell the pituitary to release its stored GH. They create the pulse.

Using them together does amplify GH release in people. In a 1990 study of 18 healthy men, low doses of the original GHRP (the hexapeptide now called GHRP-6) given with GHRH released GH synergistically, more than either produced alone. Community guides add that the pulse stays within physiological norms, unlike the steady levels from exogenous HGH; that's reasonable on mechanism but untested.

Not all GHRPs behave the same way. The table below summarizes what small human and animal studies and user reports describe.

The anabolic effect here is indirect. GH itself is only mildly anabolic. A 2008 systematic review of trials in healthy young adults found GH added about 2.1 kg of lean body mass but didn't improve strength or exercise capacity, and it caused more fluid retention and fatigue; some of that lean mass may be water. Lifters mostly report other benefits: better sleep, healthier joints and tendons (GH raises collagen synthesis), and easier fat loss. None of that has been measured as added muscle in healthy lifters. For why users cycle these peptides, see our page on peptide cycling strategies.

Tier 3 & The Experimentals: Chasing Myostatin

Now we're getting into the more speculative side of things. Myostatin is a protein that acts as the body's natural brake on muscle growth. In theory, inhibiting myostatin could lead to unchecked muscle gain.

Peptides like Follistatin-344 and the discontinued drug candidate ACE-031 were designed to do just this. The animal data are striking; myostatin-deficient Belgian Blue cattle are the usual example. The human record for these two is weak. ACE-031's trial in boys with Duchenne muscular dystrophy showed only non-significant trends toward more lean mass and was stopped over nosebleeds and small dilated blood vessels (telangiectasias).

The wider field has moved on, though not toward the products lifters can buy. On September 11, 2026, FDA approved apitegromab (Isembyld), an antibody that targets myostatin, for spinal muscular atrophy in patients 2 and older already on an SMN2-targeted treatment. FDA noted a higher risk of fractures in treated patients. In the Phase 2 BELIEVE trial (507 adults with obesity, published in 2026), adding bimagrumab, an antibody that blocks activin type II receptors, to semaglutide largely preserved lean mass, while semaglutide alone lost more.

Neither result comes from healthy lifters, and both drugs are antibodies given by IV infusion (one a prescription medicine, the other still investigational), not the research-grade follistatin peptides sold online. As of October 2026, the evidence that research-grade myostatin inhibitors produce significant results in healthy adult lifters is thin, and WADA bans myostatin inhibitors at all times (S4.3). The hype is still ahead of the science.

We also have the "indirect" players: the recovery peptides like BPC-157 and TB-500. Their claimed value isn't direct muscle growth but healing the tendonitis, sprains and strains that keep people from training heavy and consistently. The evidence is mostly animal. BPC-157 sped healing of cut Achilles tendons in a 2003 rat study, and as of October 2026 its human data are three small uncontrolled pilots. FDA says it has found no human exposure data for the TB-500 fragment. Any payoff for muscle would come indirectly, through more consistent training, and that hasn't been measured.

Stacking for Synergy, Not Replacement

No single peptide has been shown to produce anything like the results of a testosterone and nandrolone (Deca) cycle. That doesn't make peptides useless, but their effects are smaller and far less certain.

Stacks commonly described on forums include:

• A foundational stack: A GHRH/GHRP combo like CJC-1295 no DAC + Ipamorelin is the most common base. Users report better sleep, recovery and joint comfort, and a leaner look. No trial has tested this combination for body composition.
• Adding IGF-1 DES: Some users add post-workout IGF-1 DES injected into the trained muscles, aiming for localized growth. This adds the hypoglycemia risk described above and has no human data behind it.
• The durability factor: During a heavy strength block, some add BPC-157 hoping to keep elbows and knees healthy enough to keep training. That rests on rodent data and user reports.

The usual community view is that a peptide stack is gentler than a full AAS cycle and builds much less mass. The side-effect half of that comparison is mostly anecdotal, since long-term safety data for these peptides don't exist. Our page on long-term effects of peptides versus steroids covers what is known, and the main peptides vs. anabolic steroids comparison explains the mechanisms in more depth.

Comparison table